Apnimed (APMD) director details trust stakes and large options
Rhea-AI Filing Summary
Apnimed, Inc. (APMD) director Lawrence G. Miller filed an initial Form 3 reporting his existing equity interests. Indirect holdings include 10,845 shares of Series A Preferred Stock and multiple blocks of Class A Common Stock held through several irrevocable family trusts, for which he disclaims beneficial ownership except to the extent of any pecuniary interest. The filing also lists several stock options to buy Class A Common Stock, including options over 688,042 shares at an exercise price of $1.00 per share expiring in 2029, with other options at higher exercise prices and later expirations. The Series A Preferred Stock is convertible into Class A Common Stock on a one-for-one basis and will convert immediately prior to the closing of an initial public offering without additional consideration.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series A Preferred Stock F2, F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F4 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F5 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F6 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F7 | -- | -- | -- |
| holding | Class A Common Stock F1 | -- | -- | -- |
| holding | Class A Common Stock F1 | -- | -- | -- |
| holding | Class A Common Stock F1 | -- | -- | -- |
| holding | Class A Common Stock F1 | -- | -- | -- |
| holding | Class A Common Stock F1 | -- | -- | -- |
Footnotes (7)
- F1. The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.
- F2. Each share of Series A Preferred Stock is convertible into Class A Common Stock on a one-for-one basis at the option of the holder, and will convert immediately prior to the closing of the initial public offering into the number of shares shown in Column 3 without payment of additional consideration. The Series A Preferred Stock has no expiration date.
- F3. 100% of the shares subject to the option are fully vested.
- F4. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after December 22, 2022, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F5. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after December 21, 2023, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F6. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after September 17, 2025, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F7. The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 24 months after June 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Key Figures
Key Terms
Series A Preferred Stock financial
Class A Common Stock financial
Stock Option (Right to Buy) financial
beneficial ownership financial
pecuniary interest financial
FAQ
What does the Form 3 filing by Lawrence G. Miller report for Apnimed, Inc. (APMD)?
What indirect Class A Common Stock holdings are reported for Lawrence G. Miller in APMD?
What key stock option position does Lawrence G. Miller hold in Apnimed (APMD)?
Are all of Lawrence G. Miller’s Apnimed stock options fully vested?
AI-generated analysis. How Rhea-AI works. Not financial advice.